Gilead Sciences Inc.

GILD-Q

NASDAQ:GILD

67.08
1.15 (1.74%)
Gilead Sciences is an American biopharmaceutical company that discovers, develops and commercializes drugs.
More at Wikipedia

Analysis and Opinions about GILD-Q

Signal
Opinion
Expert
TOP PICK
TOP PICK
February 13, 2014

One of the world’s largest bio pharmaceutical companies. Primary area is in HIV AIDS, but they just had their hepatitis C drug approved in December. This will mean tons of revenue in the billions and earnings growth. Expects a 30% growth rate. Trading at 22X earnings, which is a pretty compelling valuation.

One of the world’s largest bio pharmaceutical companies. Primary area is in HIV AIDS, but they just had their hepatitis C drug approved in December. This will mean tons of revenue in the billions and earnings growth. Expects a 30% growth rate. Trading at 22X earnings, which is a pretty compelling valuation.

Stan Wong
Director & Portfolio Manager, Private Wealth Management, ScotiaMcleod
Price
$82.550
Owned
Yes
BUY
BUY
December 12, 2013

One of the larger biotech companies. Biotech has been outperforming pharma. You can also look at BBH for exposure to the sector. Just pulled back into the moving averages.

One of the larger biotech companies. Biotech has been outperforming pharma. You can also look at BBH for exposure to the sector. Just pulled back into the moving averages.

David Burrows
President & Chief Investment Strategist, Barometer Capital Management
Price
$70.270
Owned
Unknown
DON'T BUY
DON'T BUY
October 28, 2013

Likes their technology and products. When he models out the prospects for their new HEP C drug the numbers don’t work. Thinks the new product is already built in.

Likes their technology and products. When he models out the prospects for their new HEP C drug the numbers don’t work. Thinks the new product is already built in.

Ian Ainsworth
Vice President, Investments, MacKenzie Financial Corp.
Price
$68.731
Owned
No
BUY
BUY
May 9, 2013

Biotech group has been performing extremely well. There is growth and there is an expectation that they will be bought by a traditional drug company. You are buying something for growth here. Prefers to own the group, such as XBI-N, an ETF.

Biotech group has been performing extremely well. There is growth and there is an expectation that they will be bought by a traditional drug company. You are buying something for growth here. Prefers to own the group, such as XBI-N, an ETF.

David Burrows
President & Chief Investment Strategist, Barometer Capital Management
Price
$52.790
Owned
No
COMMENT
COMMENT
October 2, 2012

Anybody who bought this stock over the past number of years has made a profit because this one is near its historical highs. Company doesn’t interest him because it has done too well. Did a takeover which muddied the balance sheet so it is pretty ugly. Insiders have been selling an awful lot of the company.

Anybody who bought this stock over the past number of years has made a profit because this one is near its historical highs. Company doesn’t interest him because it has done too well. Did a takeover which muddied the balance sheet so it is pretty ugly. Insiders have been selling an awful lot of the company.

Benj Gallander
President, Contra the Heard Investment Letter
Price
$69.175
Owned
No
BUY
BUY
February 19, 2009
Likes Bio Pharma and ethical pharmaceutical companies. Good diversity in their product lines. Good underlying growth.
Likes Bio Pharma and ethical pharmaceutical companies. Good diversity in their product lines. Good underlying growth.
David Burrows
President & Chief Investment Strategist, Barometer Capital Management
Price
$49.040
Owned
Unknown
COMMENT
COMMENT
December 1, 2008
Trading down 7.1% on a one-year basis and 20 X forward earnings.
Trading down 7.1% on a one-year basis and 20 X forward earnings.
David Burrows
President & Chief Investment Strategist, Barometer Capital Management
Price
$42.460
Owned
Unknown
Showing 226 to 232 of 232 entries